ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO1031

Impact of Hyperphosphatemia Severity on Serum Phosphorus Reduction with Sucroferric Oxyhydroxide: A Subgroup Analysis of the VERIFIE Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Messa, Piergiorgio, Maggiore Hospital, Milan, Italy
  • Vervloet, Marc G., Amsterdam University Medical Center, Overveen, Netherlands
  • Ketteler, Markus, Robert-Bosch-Krankenhaus, Stuttgart, Germany
  • Boletis, John N., Laiko General Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece
  • De Francisco, Angel Luis M., Hospital Univ. Marques de Valdecilla, Santander, CTB, Spain
  • Kalra, Philip A., Salford Royal Hospital NHS Trust, Salford, United Kingdom
  • Cannata-Andia, Jorge B., University of Oviedo, Oviedo, Spain
  • Stauss-Grabo, Manuela, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany
  • Derlet, Anja, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany
  • Walpen, Sebastian, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland
  • Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Rottembourg, Jacques B., Groupe Hospitalier Pitié-Salpêtrière, Nephrology, Paris, France
  • Wanner, Christoph, University Hospital, Wuerzburg, Germany
  • Fouque, Denis, University Claude Bernard, Pierre Benite, France

Sucroferric oxyhydroxide (SFOH) is an iron-based phosphate binder indicated for the treatment of hyperphosphatemia in dialysis patients.


VERIFIE is a non-interventional, prospective, multicenter, European cohort study evaluating the real-world safety and effectiveness of SFOH in dialysis patients with hyperphosphatemia. This interim analysis, performed 24 months after study initiation, evaluated serum phosphorus (sP) changes during SFOH treatment in 4 subgroups of patients stratified according to their sP levels at baseline (>4.5 to ≤5.5 mg/dL; >5.5 to ≤7.0 mg/dL; >7.0 to ≤8.5 mg/dL; >8.0 mg/dL).


In total, 874 patients who received ≥1 dose of SFOH and had effectiveness follow-up data available, were included in the subgroup analysis, which evaluated sP changes during the first 12 months of treatment. Approximately 40% of patients received concomitant phosphate binders (in addition to SFOH) during the study. Statistically significant (p<0.001) reductions in sP from baseline through Month 12 were observed among patients with baseline sP >5.5 to ≤7.0 mg/dL, >7.0 to ≤8.5 mg/dL or >8.5 mg/dL. Smaller reductions in sP were observed in the >4.5 to ≤5.5 mg/dL subgroup (Figure). Overall, reductions from baseline in mean sP were greater among patients with higher baseline sP levels.


This subgroup analysis demonstrated that treatment with SFOH can lower sP in real-world dialysis patients with hyperphosphatemia, regardless of their baseline sP levels, and these reductions were sustained over 12 months.


  • Commercial Support